Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 60%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. is positioned for strong revenue growth, particularly from its Signatera molecular residual disease test, which saw a remarkable increase of 21,500 volumes quarter-over-quarter in Q3, reflecting a year-over-year growth of 54%. The company has indicated a potential for expanded reimbursement coverage across additional cancer types, which is expected to enhance average selling prices and improve gross margins. Furthermore, Natera's recent financial performance includes an approximately $80 million revenue beat in Q3 and a significant upward revision of its 2025 revenue guidance by $160 million, underscoring the firm's robust growth trajectory and market confidence.

Bears say

Natera Inc faces potential margin erosion due to reductions in in-network pricing as its total addressable market (TAM) expands, particularly with the inclusion of more average risk patients. The company's growth may be further hindered by regulatory setbacks or delays in product launches, which could negatively impact its ability to expand internationally and achieve market adoption in emerging regions. Furthermore, any shortfall in financial performance or adverse regulatory news presents a significant risk that could adversely affect the company's stock value.

Natera (NTRA) has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 60% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 15 analysts, Natera (NTRA) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $235.87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $235.87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.